Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Specimen Handling 186pembrolizumab 151Magnetic Resonance Spectroscopy 151Carboplatin 114Biopsy 104Cyclophosphamide 96Cisplatin 88Paclitaxel 79Gemcitabine 71Bevacizumab 68fludarabine 60Nivolumab 58Fluorouracil 51Radiotherapy 49Dexamethasone 47Capecitabine 47Pemetrexed 46Oxaliplatin 44Docetaxel 44Rituximab 43Leucovorin 41Doxorubicin 40venetoclax 39durvalumab 39atezolizumab 39Temozolomide 32Standard of Care 32Radiation 32Cetuximab 32130-nm albumin-bound paclitaxel 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Loratadine × 30 days × Clear all
NCT04211259 2026-05-29

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Rutgers, The State University of New Jersey

Phase EARLY_PHASE1 Recruiting
70 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡